Bulk Active Ingredients from Pfizer CentreSource
Pfizer CentreSource (PCS) has an established reputation for providing high quality Bulk Active Ingredients.
Pfizer CentreSource (PCS) has an established reputation for providing high quality Bulk Active Ingredients to the global fine chemicals marketplace. Our broad range of corticosteroids and hormonal steroids is used in a wide variety of sterile-manufacturing-packaging indications. Pfizer is a leading supplier of fine chemicals, steroid APIs, and steroid intermediates. Pfizer’s strength among steroid API suppliers is derived from our backward-integrated production platform based on soy sterol bioconversion and innovative chemical synthesis.
PCS corticosteroid offerings include dexamethasone, hydrocortisone, hydrocortisone acetate, prednisone, and spironolactone.
Hormonal Steroid products from PCS include: progesterone, megestrol acetate, testosterone, testosterone cypionate, and testosterone propionate.
PCS also supplies two grades of neomycin sulfate antibiotic, including Neomycin Sulfate Powder USP/EP and Neomycin Sulfate Micronized USP/EP.
For advanced intermediates, Pfizer’s unique GMP compliant process utilizes soybean-derived sterols and proprietary fermentation processes to create a very broad intermediate platform. This is done at a large scale, a far more efficient process than operations used by competing steroid manufacturers.
Pfizer CentreSource (PCS)
Website: www.pfizercentresource.comEmail:Kenneth.F.Ball@pfizer.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
